Acceleron Pharma Inc. (XLRN) Hit 52-Week High at $48.80

June 29, 2018 - By Don Salinas

Acceleron Pharma Inc. (NASDAQ:XLRN) Corporate Logo

During Q1 2018 the big money sentiment increased to 1.27. That’s change of 0.18, from 2017Q4’s 1.09. 13 investors sold all, 39 reduced holdings as Acceleron Pharma Inc. ratio improved. 42 rose holdings while 24 funds amassed holdings. Funds hold 38.30 million shares thus 0.44% more from 2017Q4’s 38.14 million shares.
Riverhead Cap Mgmt Limited Company holds 0% of its capital in Acceleron Pharma Inc. (NASDAQ:XLRN) for 166 shs. Bankshares Of Montreal Can accumulated 326 shs. Franklin Res invested in 435,577 shs or 0.01% of the stock. Barclays Public Limited Company owns 0% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 28,105 shs. Hillhouse Cap Management holds 0.48% or 700,000 shs in its capital. California State Teachers Retirement reported 0% stake. 38,809 are held by Citigroup. Invesco Limited has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Pnc Financial Services Group holds 0.01% of its capital in Acceleron Pharma Inc. (NASDAQ:XLRN) for 131,119 shs. 8,494 were accumulated by Teacher Retirement Of Texas. Sabby Mngmt Ltd Llc holds 8,646 shs. Great Point Partners Ltd Liability Company holds 0% or 462,245 shs in its capital. Voya Investment Ltd Limited Liability Company owns 16,011 shs. Winslow Evans And Crocker holds 0% or 1,616 shs. Metropolitan Life Insurance New York reported 0% stake.

Acceleron Pharma Inc. registered $4.08 million net activity with 0 buys and 12 sales since January 2, 2018. Another trade for 11,000 shs valued at $495,000 was sold by Rovaldi Christopher. MCLAUGHLIN KEVIN F sold $153,792 worth of stock. Another trade for 1,204 shs valued at $46,232 was sold by Quisel John D. Kumar Ravindra sold $46,205 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) on Tuesday, April 3. 4,633 shs valued at $197,868 were sold by Sherman Matthew L on Wednesday, January 3.

The company Acceleron Pharma Inc. (NASDAQ:XLRN) hit yearly high with $52.70 PT or 8.00 % above today’s $48.80 price per share. On Jun, 29 it was published by Barchart.com. The company has $2.23B market cap. At $52.70 stock PT, the company valuation changes by $178.72 million more.

XLRN hit $48.8 during the last trading session after $14.82 change.Acceleron Pharma Inc. is uptrending after having risen 37.77% since June 29, 2017. XLRN has 3.15M volume or 862.44% up from normal. The stock outperformed the S&P500 by 25.20%.

On August, 2 Acceleron Pharma Inc. (NASDAQ:XLRN)’s earnings report is anticipated by WallStreet, Zacks reports. EPS of $-0.64 is 16.88 % up from 2017’s $-0.77 EPS. Wall Street forecasts 10.34 % negative EPS growth as of August, 2.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Coverage

A total of 7 analysts rate Acceleron Pharma (NASDAQ:XLRN) as follows: 5 “Buy”, 2 “Hold” and 0 “Sell”. Тherefore 71% are bullish. The firm has $63 highest and $40 lowest target. The avg target $52 is 6.56% above the last ($48.8) price. (NASDAQ:XLRN) has 9 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Wednesday, March 28 the stock has “Buy” rating by H.C. Wainwright. On Tuesday, May 22 the rating was initiated by Oppenheimer with “Hold”. The stock rating was maintained by Citigroup with “Buy” on Thursday, March 1. On Monday, February 26 the firm has “Overweight” rating by JP Morgan given. On Wednesday, February 28 the stock has “Overweight” rating by Barclays Capital. On Friday, June 29 the firm has “Neutral” rating given by Goldman Sachs. On Monday, January 8 the firm earned “Buy” rating by H.C. Wainwright. The company rating was maintained by H.C. Wainwright on Wednesday, February 28. On Friday, June 29 the stock has “Outperform” rating by Credit Suisse.

For more Acceleron Pharma Inc. (NASDAQ:XLRN) news posted recently go to: Businesswire.com, Streetinsider.com, Benzinga.com, Globenewswire.com or Benzinga.com. The titles are as follows: “Acceleron to Present Preliminary Data on ACE-083 at the 2018 Annual Meeting of the Peripheral Nerve Society” posted on June 26, 2018, “Acceleron Pharma (XLRN) Highlights Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia” on June 15, 2018, “10 Biggest Price Target Changes For Friday” with a publish date: June 29, 2018, “Market Trends Toward New Normal in RCI Hospitality, Phillips 66 Partners LP, Acceleron Pharma, Destination …” and the last “Acceleron Pharma Rallies After Phase 3 MDS Data, But Goldman Sachs Still Isn’t Buying” with publication date: June 29, 2018.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases.The firm is valued at $2.23 billion. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases.Last it reported negative earnings. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

Acceleron Pharma Inc. (NASDAQ:XLRN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.